BrUOG 397

Neoadjuvant ipilimumab and nivolumab with low dose SBRT fir resectable stage IB=III NSCLC. Closed to accrual. Open to biospecimen donation.
Status:

Open

Trial Type:

Contact:

Christopher Azzoli, MD
cazzoli@brownhealth.org